Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine-Reference-Cited by-同舟云学术

Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine

Published:2021-04 Issue:15 Volume:39 Page:2048-2059
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Hamidi Ahd,Hoeksema Femke,Velthof Pim,Lemckert Angelique,Gillissen Gert,Luitjens Alfred,Bines Julie E.,Pullagurla Swathi R.,Kumar Prashant,Volkin David B.,Joshi Sangeeta B.,Havenga Menzo,Bakker Wilfried A.M.,Yallop Christopher

Funder

Bill & Melinda Gates Foundation

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference52 articles.

1. Estimating global, regional and national rotavirus deaths in children aged <5 years: Current approaches, new analyses and proposed improvements;Clark;PLoS ONE,2017

2. GAVI-supported rotavirus vaccines profiles to support country decision making - rotavirus-vaccine-profilespdf.pdf. 2019 [cited 2020 April 02]; Available from: https://www.gavi.org/our-alliance/market-shaping/product-information-vaccines-cold-chain-equipment.

3. Immunogenicity of four doses of oral poliovirus vaccine when co-administered with the human neonatal rotavirus vaccine (RV3-BB);Cowley;Vaccine,2019

4. Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries?;Steele;Hum Vaccin Immunother,2019

5. Polio endgame: Lessons for the global rotavirus vaccination program;Jiang;Vaccine,2019

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication;Human Vaccines & Immunotherapeutics;2022-12-28

2. Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study;The Lancet Infectious Diseases;2022-05

3. Modeling the long-term 2-8 °C stability profiles of a live, rotavirus vaccine candidate (RV3-BB) in various liquid formulations via extrapolations of real-time and accelerated stability data;Biologicals;2022-01

4. Rotavirus vaccines: progress and new developments;Expert Opinion on Biological Therapy;2021-09-10

5. Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries;Human Vaccines & Immunotherapeutics;2021-04-16